Successful pre-surgical treatment with carboplatin and gemcitabine chemotherapy for a patient with muscle-invasive bladder cancer and severe renal dysfunction.
Shota ToriiTomoya NaritaTakamasa HommaTeruhisa KinoshitaAya Torii-GotoHideki EsakiTakashi SakakibaraAtsuya KondoNorio TakimotoPublished in: International cancer conference journal (2024)
Radical cystectomy is the standard treatment for muscle-invasive bladder cancer, and pre-surgical treatment can improve survival. Carboplatin and gemcitabine chemotherapy is considered an effective, safe treatment for patients ineligible for cisplatin-based chemotherapy owing to reduced renal function. However, there is limited evidence on pre-surgical treatment with carboplatin and gemcitabine chemotherapy with glomerular filtration rates < 30 mL/min. We discuss the treatment of a patient who did not undergo surgery owing to bladder tumor size of 12 cm (cT3bN0M1a) and severe renal dysfunction (serum creatinine: 2.57 mg/dL, estimated glomerular filtration rate: 20.2 mL/min/1.73 m 2 ). After the patient received two courses of carboplatin and gemcitabine chemotherapy, the bladder tumor size had reduced by 60%. No nausea or renal dysfunction was observed; febrile neutropenia improved with antibiotic therapy and granulocyte colony-stimulating factor. Then, he could undergo robot-assisted radical cystectomy after the pre-surgical chemotherapy treatment. Pre-surgical treatment with carboplatin and gemcitabine chemotherapy is a viable treatment option for patients with muscle-invasive bladder cancer and severe renal dysfunction.
Keyphrases
- locally advanced
- muscle invasive bladder cancer
- phase ii study
- squamous cell carcinoma
- robot assisted
- chemotherapy induced
- case report
- oxidative stress
- spinal cord injury
- randomized controlled trial
- metabolic syndrome
- stem cells
- magnetic resonance imaging
- newly diagnosed
- early onset
- clinical trial
- magnetic resonance
- ejection fraction
- endothelial cells
- phase iii
- open label
- study protocol
- smoking cessation
- combination therapy
- replacement therapy
- coronary artery bypass
- positron emission tomography
- uric acid
- surgical site infection
- pet ct
- recombinant human